Transcept Pharmaceuticals Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 33

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $27.2M

Transcept Pharmaceuticals General Information

Description

Developer of pharmaceuticals designed to address therapeutic needs in the field of neuroscience. The company develops a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine (DHE) as the active drug, thereby enabling patients with migraine to get treated effectively.

Contact Information

Formerly Known As
Novacea, TransOral Pharmaceuticals
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1003 West Cutting Boulevard
  • Suite 110
  • Richmond, CA 94804
  • United States
+1 (510)
Primary Industry
Drug Delivery
Vertical(s)
Corporate Office
  • 1003 West Cutting Boulevard
  • Suite 110
  • Richmond, CA 94804
  • United States
+1 (510)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Transcept Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Merger/Acquisition 30-Oct-2014 $27.2M Completed Generating Revenue
11. Merger/Acquisition 18-Sep-2013 Cancelled Generating Revenue
10. 2PO 25-Apr-2012 Completed Generating Revenue
9. Reverse Merger 30-Jan-2009 Completed Generating Revenue
8. Later Stage VC (Series D) 08-Mar-2007 Completed Generating Revenue
7. Debt - General 05-Jun-2006 Completed Generating Revenue
6. Later Stage VC (Series C) 17-Jan-2006 Completed Generating Revenue
5. Early Stage VC 02-Jan-2004 Completed Generating Revenue
4. Early Stage VC (Series B) 04-Nov-2002 $36M $36M Completed Generating Revenue
3. Early Stage VC (Series A) $9K Completed Product Development
To view Transcept Pharmaceuticals’s complete valuation and funding history, request access »

Transcept Pharmaceuticals Patents

Transcept Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20120302616-A1 Method of treatment of obsessive compulsive disorder with ondansetron Inactive 03-Dec-2010
WO-2012075288-A1 Method of treatment of obsessive compulsive disorder with ondansetron Inactive 03-Dec-2010
US-20120128778-A1 Compositions and methods for once-daily administration of a trilayer osmotic tablet Inactive 23-Nov-2010
WO-2012071220-A1 Compositions and methods for once-daily administration of a trilayer osmotic tablet Inactive 23-Nov-2010
US-20120128730-A1 Compositions and methods for once-daily treatment of obsessive compulsive disorder with ondansetron Inactive 23-Nov-2010 A61K9/0004
To view Transcept Pharmaceuticals’s complete patent history, request access »

Transcept Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Transcept Pharmaceuticals Former Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Hamilton BioVentures Venture Capital Minority
InterWest Partners Venture Capital Minority
Montreux Equity Partners Growth/Expansion Minority
New Enterprise Associates Venture Capital Minority
New Leaf Venture Venture Capital Minority
You’re viewing 5 of 15 investors. Get the full list »

Transcept Pharmaceuticals Acquisitions (2)

Transcept Pharmaceuticals’s most recent deal was a Reverse Merger with Paratek Pharmaceuticals for . The deal was made on 30-Oct-2014.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Paratek Pharmaceuticals 30-Oct-2014 Reverse Merger Pharmaceuticals
Novacea 02-Feb-2009 Merger/Acquisition Drug Discovery
To view Transcept Pharmaceuticals’s complete acquisitions history, request access »

Transcept Pharmaceuticals FAQs

  • When was Transcept Pharmaceuticals founded?

    Transcept Pharmaceuticals was founded in 2001.

  • Where is Transcept Pharmaceuticals headquartered?

    Transcept Pharmaceuticals is headquartered in Richmond, CA.

  • What is the size of Transcept Pharmaceuticals?

    Transcept Pharmaceuticals has 33 total employees.

  • What industry is Transcept Pharmaceuticals in?

    Transcept Pharmaceuticals’s primary industry is Drug Delivery.

  • Is Transcept Pharmaceuticals a private or public company?

    Transcept Pharmaceuticals is a Private company.

  • What is the current valuation of Transcept Pharmaceuticals?

    The current valuation of Transcept Pharmaceuticals is .

  • What is Transcept Pharmaceuticals’s current revenue?

    The current revenue for Transcept Pharmaceuticals is .

  • How much funding has Transcept Pharmaceuticals raised over time?

    Transcept Pharmaceuticals has raised $187M.

  • Who are Transcept Pharmaceuticals’s investors?

    Hamilton BioVentures, InterWest Partners, Montreux Equity Partners, New Enterprise Associates, and New Leaf Venture are 5 of 15 investors who have invested in Transcept Pharmaceuticals.

  • When was Transcept Pharmaceuticals acquired?

    Transcept Pharmaceuticals was acquired on 30-Oct-2014.

  • Who acquired Transcept Pharmaceuticals?

    Transcept Pharmaceuticals was acquired by Paratek Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process